Stock symbol: TSX: TOS
Outstanding shares: 47,863,402
QUEBEC, April 30 /CNW Telbec/ - Mr. R.M. (Ric) Rumble, President and
Chief Executive Officer of TSO3 Inc. ("TSO3") (TSX: TOS), announced today
during the Company's annual shareholders meeting that the Company intends to
add a new sterilization cycle to the TSO3 STERIZONE(R) 125L Sterilizer. The
new cycle which is currently under development, will enable hospitals to use
the system on an expanded range of delicate medical devices. This increased
utility will reduce hospital operating cost while opening additional markets
for the Company.
The new cycle is expected to be submitted for clearance to regulatory
agencies in Canada and the United States later this year. Once cleared, this
cycle will be added to all new TSO3 STERIZONE(R) Sterilizers shipped from the
Company. In addition, the Company intends to make the cycle available to
existing customers as a field upgrade with minimal disruption to current
"Adding this new cycle will address key customer needs," explains Mr.
Rumble. "First, our customers are looking for a system that will provide low
temperature sterilization for a wide array of medical devices, including the
most delicate instruments without the requirement to use costly and toxic
sterilizing agents. The new cycle is intended to provide efficacious
sterilization without increasing wear and tear on these valuable instruments
and without using toxic chemistries."
In addition to providing high sterilization efficacy and material
compatibility, TSO3's new cycle is expected to offer faster turnaround times
when compared to Ethylene Oxide sterilization cycles, some of these cycles can
take longer than eighteen hours to complete.
Mr. Rumble said that customers are also looking for a safe and
environmentally-friendly sterilization method. "One of the many strengths of
our system is that we use only oxygen, water and electricity to create an
ozone-based sterilization process that is safe for staff to use, highly
effective, and leaves no toxic residues after cycle completion. This sharply
contrasts with ethylene oxide sterilization - a commonly used low temperature
method that uses a toxic, flammable gas and requires environmental and
personal safety apparatus to operate. For all these reasons, our TSO3
STERIZONE(R) Sterilization System offers a compelling alternative to ethylene
Recently, TSO3 also received approval from Health Canada to expand the
intended use of the TSO3 STERIZONE(R) Sterilizer to include multi-channel
flexible endoscopes. "This approval and our projects under development are all
focused on one primary objective - to provide our customers with solutions
that meet their needs for sterile efficacy, material compatibility and timely
throughput that is cost effective and environmentally safe. This is all
consistent with TSO3's vision is to create the Improved Standard in Healthcare
Sterilization," said Mr. Rumble.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers
in the hospital environment.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by
the US Food and Drug Administration and by Health Canada for sterilization of
metal and heat sensitive instruments and devices with diffusion-restricted
spaces, such as the hinged portion of haemostats, forceps and scissors and
rigid endoscopes having a single stainless steel lumen as small as 0.9 mm
internal diameter and 485 mm long is in commercialization phase for this first
product since 2006.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Marc Boisjoli, Vice President Finance and Chief
Financial Officer, (418) 651-0003, ext. 228, email@example.com; Frédéric
Tremblay, 514 658-8033, firstname.lastname@example.org; Source: TSO3 Inc.